- Home
- MLTX vs NVCR Comparison
MLTX vs NVCR Comparison
Compare MLTX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLTX
- NVCR
- Stock Information
- Founded
- MLTX 2021
- NVCR 2000
- Country
- MLTX Switzerland
- NVCR Switzerland
- Employees
- MLTX N/A
- NVCR N/A
- Industry
- MLTX Biotechnology: Pharmaceutical Preparations
- NVCR Medical/Dental Instruments
- Sector
- MLTX Health Care
- NVCR Health Care
- Exchange
- MLTX Nasdaq
- NVCR Nasdaq
- Market Cap
- MLTX 2.3B
- NVCR 1.9B
- IPO Year
- MLTX N/A
- NVCR 2015
- Fundamental
- Price
- MLTX $38.60
- NVCR $17.38
- Analyst Decision
- MLTX Strong Buy
- NVCR Buy
- Analyst Count
- MLTX 8
- NVCR 6
- Target Price
- MLTX $80.50
- NVCR $32.83
- AVG Volume (30 Days)
- MLTX 434.1K
- NVCR 884.7K
- Earning Date
- MLTX 05-20-2025
- NVCR 04-24-2025
- Dividend Yield
- MLTX N/A
- NVCR N/A
- EPS Growth
- MLTX N/A
- NVCR N/A
- EPS
- MLTX N/A
- NVCR N/A
- Revenue
- MLTX N/A
- NVCR $621,711,000.00
- Revenue This Year
- MLTX $103.42
- NVCR $2.90
- Revenue Next Year
- MLTX N/A
- NVCR $10.47
- P/E Ratio
- MLTX N/A
- NVCR N/A
- Revenue Growth
- MLTX N/A
- NVCR 18.27
- 52 Week Low
- MLTX $31.42
- NVCR $14.17
- 52 Week High
- MLTX $58.26
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- MLTX 53.31
- NVCR 48.17
- Support Level
- MLTX $36.75
- NVCR $16.19
- Resistance Level
- MLTX $42.90
- NVCR $17.70
- Average True Range (ATR)
- MLTX 2.06
- NVCR 0.85
- MACD
- MLTX 0.03
- NVCR 0.06
- Stochastic Oscillator
- MLTX 58.04
- NVCR 42.53
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.